ELUVIA™

Drug-Eluting Vascular Stent System

Superior Results in the First Head-to-Head DES SFA Trial

Learn more about the IMPERIAL Clinical Trial

Learn more about the IMPERIAL Clinical Trial

The Eluvia Drug-Eluting Stent System showed SUPERIOR results in the first head-to-head DES SFA Trial.


IMPERIAL Trial: A global randomized controlled multi-center trial with 2:1 randomization of the Eluvia™ Drug-Eluting Stent against Cook Medical’s Zilver™ PTX™ Stent, single-blind, non-inferiority design; independent core lab adjudication.
Superiority determined in a post hoc analysis that was specified prior to unblinding. 12-Month Primary Patency rate of 86.8% in the Eluvia arm vs. 77.5% in the Zilver PTX arm (p-value = 0.0144).

Product Overview

Product Overview

Advanced drug-eluting technology for peripheral artery disease.

Button
Sustained Drug Release

Sustained Drug Release

Delivers paclitaxel when restenosis is most likely to occur.

Button
Product Design

Product Design

Built on the proven InnovaTM Stent platform.

Button
Top